Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 14, Number 11—November 2008
Research

Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany

Barbara Eker, Johannes Ortmann, Giovanni B. Migliori, Giovanni Sotgiu, Ralf Muetterlein, Rosella Centis, Harald Hoffmann, Detlef Kirsten, Tom Schaberg, Sabine Ruesch-Gerdes, Christoph LangeComments to Author , and for the German TBNET Group
Author affiliations: Research Center Borstel, Borstel, Germany (B. Eker, S. Ruesch-Gerdes, C. Lange); Karl-Hansen-Clinic, Bad Lippspringe, Germany (J. Ortmann); World Health Organization Collaborating Center for TB and Lung Diseases, Tradate, Italy (G.B. Migliori, R. Centis); Sassari University, Sassari, Italy (G. Sotgiu); Regional Hospital, Pasberg, Germany (R. Muetterlein); Asklepios-Hospital, Gauting, Germany (H. Hoffmann); Hospital Großhansdorf, Großhansdorf, Germany (D. Kirsten); Deakoness Hospital, Rotenburg, Germany (T. Schaberg);

Main Article

Table 2

Logistic regression analysis of the association of treatment failure (death and failure) with potential explanatory factors*

Variables Crude OR (95% CI) Adjusted OR (95% CI)
Male gender 4.46 (0.56–35.5) 5.8 (0.61–56.6)
Age, y 1.05 (1.01–1.09) 1.06 (1.01–1.1)
Immigrant status 1.18 (0.13–10.2) 0.7 (0.07–6.6)
HIV seropositivity 5 (0.76–32.6) 2.5 (0.28–22.1)
Previous TB treatment >30 d 0.7 (0.26–2.2) 0.4 (0.11–1.3)
Streptomycin resistance 1.35 (0.15–11.4) 1.18 (0.13–10.69)
Ethambutol resistance 1.74 (0.52–5.7) 0.99 (0.29–3.3)
Pyrazinamide resistance 1.65 (0.57–4.7) 1.08 (0.35–3.3)
Fluoroquinolone resistance 1.67 (0.32–8.6) 0.86 (0.09–7.7)
Resistance to injectable second-line drugs 1.16 (0.3–4.5) 1.28 (0.31–5.2)
Resistance to all second-line drugs 1.18 (0.34–3.9) 1.35 (0.37–4.8)

*OR, odds ratio; CI, confidence interval; TB, tuberculosis.

Main Article

1Additional German Tuberculosis Network European Trials group (TBNET) contributors: R. Eberhardt, Thorax-Clinic-Heidelberg, Heidelberg; A. Esselmann, Pulmonary Clinic, Hemer; H. Flick, Charité, Berlin; M. Hamm, Hospital Diekholzen, Diekholzen; P. Hammerl, Hospital Immenhausen, Immenhausen; H. Hang, Hospital Schillerhöhe, Schillerhöhe; P. Hannemann, Deakoness Hospital, Neustadt; D. Hillemann, Research Center Borstel, Borstel; B. Kretz, Asklepios Hospital, Gauting; C. Laumanns, Bethania Hospital, Solingen; G. Liebetrau, Lostau Hospital, Lostau; S. Ott, Helios Clinic Emil von Behring, Berlin; A. Paulick, Pulmonary Clinic-Coswig, Coswig; M.W. Pletz, Hannover Medical School, Hannover; M. Rau, Pulmonary Clinic, Wangen; G. Rohde, Bergmannsheil Hospital, Bochum; A. de Roux, Evangelische Lungenklinik, Berlin; C. Schaudt, Hospital St. Blasien, St. Blasien; K-D.Schneider, Pulmonary Clinic, Hannover-East, Hannover; S. Stenger, University Hospital, Ulm; D. Wagner, University Hospital, Freiburg; and T. Wolf, University Hospital, Frankfurt.

Page created: July 21, 2010
Page updated: July 21, 2010
Page reviewed: July 21, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external